Nilo Ther­a­peu­tics

We know that immune dysreg­u­la­tion is implicated in a range of diseases, from diabetes to neurode­gen­er­a­tion. And we know that the brain is a principal regulator of the immune system. What we haven’t understood, until recently, is exactly how the brain senses and modulates immune responses. Nilo Ther­a­peu­tics is building on pioneering research from the Charles Zuker lab at Columbia University documenting the specific messenger molecules and neural circuits involved in promoting and suppressing inflam­ma­tion. The company plans to develop drugs that target these circuits in order to manage immune disorders such as toxic shock, cytokine storms, and rheumatoid arthritis and other autoimmune diseases.